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Abstract
Background: Rheumatoid arthritis (RA) patients failing disease modifying antirheumatic drugs (DMARDs) may
undergo anti-Tumor Necrosis Factor (anti-TNF) therapy. Using the Quebec health services administrative databases,
we examined the rates of musculoskeletal (MSD)-related hospitalizations among RA patients receiving anti-TNF,
DMARDs, and neither of those therapies (non-users).
Methods: Matched cohort analyses were performed separately in 2002–2006 and 2007–2011. In each cohort,
DMARD and non-user groups were formed to 3-1 match the anti-TNF users on age, sex, date of RA diagnosis,
high-dimensional propensity score and date of the first anti-TNF dispensation (index-date). Non-users did not use
DMARDs or anti-TNF drugs during the year before the index-date and in the 90 days post, but used at least one
of these medications in the study period.
Results: During 2002–2006, 557 anti-TNF users were matched to 1144 DMARD users and to 656 non-users,
compared to 690, 1651, and 532 patients, respectively during 2007–2011. The crude rates of MSD-related
hospitalizations in the anti-TNF, DMARD and non-users groups were respectively: 8.2/100, 6.4/100 and 10.5/100
patient-years in 2002–2006, and 6.9/100, 4.8/100, and 8.6/100 patient-years in 2007–2011. In multivariable Cox
regression models, the hazard ratios of MSD-related hospitalizations (95 % confidence interval) were: 0.95
(0.60; 1.50) for anti-TNF and 0.69 (0.46; 1.02) for DMARD users, versus non-users in 2002–06, and 0.65
(0.37; 1.14) and 0.40 (0.24; 0.66), respectively in 2007–2011.
Conclusion: The MSD-related hospitalization risk was lower in RA patients using DMARD therapy and similar
in those using anti-TNF therapy with or without DMARDs as compared to those not using either of these
therapies during the study period.
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Background
Clinical practice guidelines recommend that disease-
modifying anti-rheumatic drugs (DMARD) be intro-
duced in rheumatoid arthritis (RA) as soon as possible.
Combination therapy with DMARDs (methotrexate
+/−hydroxychloroquine +/− sulfasalazine) and/or the
addition of biologic agents that target Tumor Necrosis
Factor (TNF) is considered in patients who have an
inadequate response to DMARD monotherapy. Cortico-
steroids are also used, to manage flares and suppress
symptoms [1]
In Quebec, anti-TNF drugs were listed on the public
drug formulary for RA in 2002. Eligibility for an anti-
TNF remains active synovitis (eight or more joints),
and having failed two DMARDs including methotre-
xate [2]. As such, anti-TNF drug users would be
expected to have more severe RA compared to non-
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users, with a trend towards more prompt initiation in
more recent times [3–5].
Randomized controlled trials (RCT) and observa-
tional studies have demonstrated benefits of anti-TNF
agents in RA treatment on the basis of both disease
activity and joint damage [6, 7]. Some observational
studies have considered hospital admissions as an effect-
iveness indicator showing that anti-TNF therapy may re-
duce the rate of hospitalization, although the results remain
uncertain [8, 9].
We used a high-dimensional propensity score ap-
proach [10] with Quebec health services administra-
tive data to compare the rates of musculoskeletal
(MSD) –related hospitalizations among RA patients
receiving anti-TNF therapy, those receiving DMARDs,
and those patients who were receiving neither of
those therapies (non-users). We also compared results
across calendar time. We hypothesized that MSD-
related hospital admission rates were lower in RA pa-




We used physician and prescription drug claims, hos-
pital discharge data, and demographic records from
January 1997 to March 2012 from the provincial
health services administrative databases administered
by the Régie de l’assurane maladie du Québec
(RAMQ). In this Canadian province, coverage for out-
patient and inpatient physician services is provided
for the entire population (about 7.5 million people).
Individuals aged 65 years or older (1,106,428 individ-
uals in 2011; 90 % of that population) and those
under 65 years (2,261,786 individuals in 2011; 32 %
of that population including those who receive social
assistance, 493 212 individuals, and those who do not
have collective private drug insurance, 1,768,574
individuals, such as the self-employed), have their
prescription drugs covered by the provincial govern-
ment. Medication dispensations have been demon-
strated to be accurately and reliably recorded in the
RAMQ prescription claims database [11]. The Quebec
hospital discharge abstract database provides informa-
tion on all hospital admissions including primary and
secondary discharge diagnoses [International Classifi-
cation of Diseases (ICD), 9th revision (ICD-9) codes
until April 2006 and 10th revision (ICD-10) codes
thereafter] and admission/discharge dates. The data-
bases are linkable by a unique patient identifier. Per-
mission to link the data was obtained from the
Provincial Ethics Board, the Commission d’accès à
l’information. Approval to conduct the study was
obtained from the McGill University Health Centre
Ethics Review Board.
Study design
As anti-TNF users were expected to have failed at
least two DMARDs and to have a more severe RA
profile in the earlier years of marketing, we con-
ducted our main analyses over two separate time-
periods January 2002 - December 2006 and January
2007 - December 2011 and results were compared.
To further understand the effect of anti-TNF on the
study outcomes, we also ran our analyses over the
time-period immediately preceding the introduction
of anti-TNF medications on the Quebec drug formu-
lary, January 1998 - December 2001.
We describe the study cohort in 2002–2006. Study
cohorts of 1998–2001 and 2007–2011 are similarly
constructed. An RA cohort was first constructed in-
cluding patients 20 years of age and older who in
2002–2006 had two outpatient ICD-9 codes for RA
(714.x) at least 30 days and no more than 2 years
apart or one diagnosis (principal or secondary) from
the hospital abstract database (ICD-9 code 714.x until
April 2006 and ICD-10 codes M05.x, M06.x, M08.x,
and M09.x afterwards) [12]. Individuals who received
at least one dispensed prescription for either a
DMARD or anti-TNF during the study period were
considered in the study. The anti-TNF agents available
in Quebec during 2002–2006 were: infliximab, etanercept,
adalimumab. Certolizumab, rituximab and golimumab be-
came available in the period 2007–2011 and were also in-
cluded. The DMARDs included in the study were:
chloroquine, hydroxychloroquine, cyclophosphamide,
cyclosporine, methotrexate, minocycline, penicillamine,
auranofine, sulfasalazine, leflunomide, aurothioglucose,
aurothiomalate. Other non-anti-TNF biologic drugs were
not included in this study because of the very small num-
ber of users.
Study cohorts
Each study cohort consisted of three groups, anti-TNF,
DMARDs and non-users. Patients in the RA cohort
dispensed an anti-TNF in 2002–2006 were identified at
the first dispensation date (index date). Those covered
by the provincial drug plan for at least 1 year prior and
3 months post the index date were included and formed
the anti-TNF group (anti-TNF naïve in the previous
year). Two other groups, the DMARD and non-user
groups, were formed to match the anti-TNF group on
age (±2 years), sex, date of RA diagnosis (±90 days) and
high-dimensional propensity score (±0.05) [10]. To form
the DMARD group, for each individual in the anti-TNF
group, three anti-TNF naïve individuals (for at least
1 year before and 90 days after the date of anti-TNF
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dispensing) who used a DMARD within 90 days of the
index date of the anti-TNF individual were selected at
random from those eligible at the date of the DMARD
use (index date; for those who used more than one
DMARD within the 90-day-period, the closest date to
the anti-TNF index date was chosen). The non-user
group was constructed similarly. For each individual in
the anti-TNF group, three anti-TNF and DMARD naïve
individuals were selected at random to match the anti-
TNF individual on age, sex, date of RA and high-
dimensional propensity score as described above. The
index date of the anti-TNF individual was assigned as
the index date of the non-user individuals. Of note,
patients in the non-user group did not use an anti-TNF
or a DMARD for at least 1 year before and 90 days after
the index date, but have used at least one of these drugs
at another time during the study period as described
above. The non-users could be under therapy with other
drugs, such as corticosteroids and nonsteroidal anti-
inflammatory drugs (NSAIDs). The high-dimensional
propensity score has been proposed to adjust for indication
and confounding biases caused by missing or misclassified
information. In this study, the high-dimensional propensity
score (probability of receiving an anti-TNF) was calculated
in a multivariate logistic regression model adjusted for a
large number of covariates (500), as suggested in the
algorithm, assessed based on all diagnoses, procedures,
services and drug-dispensations recorded in the databases
and selected according to their potential to bias the
exposure-outcome relationship under study [10]. A high–
dimensional propensity score algorithm is available as
downloadable SAS software files from the Brigham and
Women’s Hospital [13]. All included patients were
required to be alive for at least 90 days past their index
date and not to have had any MSD-related hospitalization
in the prior year.
All study patients were followed from index date
until the first date of death, end of drug coverage,
switch/discontinuation of their index treatment or a
maximum of 1 year. Discontinuation of treatment was
defined as at least 90 days without the treatment and
treatment switch was a switch between the three
exposure groups (a switch between two DMARDs or
two anti-TNFs was not considered to be a treatment
switch).
Outcomes
The first hospitalization with a principal diagnosis for
any MSD reason, ICD-9 and 10 codes included in the
chapter XIII - diseases of the MSD system and connec-
tive tissue, during follow-up was the principal outcome
(Appendix 1 and Appendix 2– diagnoses found in the
study).
Patient baseline characteristics
Patient characteristics assessed at index date included:
age, sex, type of insurance plan (based on patient eli-
gibility for premium subsidies; low income patients
were those receiving premium or partial subsidies),
region of residence (urban or rural), visits to a
rheumatologist in the prior year, comorbidity (cancer,
ischemic heart disease, congestive heart failure (CHF),
peptic ulcer disease, cerebrovascular disease (CVD), atrial
fibrillation, and hematologic disorders), medication used
in the prior year [corticosteroids, gastroprotective agents
(proton pump inhibitors, misoprostol and histamine-2
receptor blocker), serotonin reuptake inhibitors (SSRI),
anticoagulants, antidiabetics, antihypertensives and
NSAIDs]. These factors were chosen because of their
potential association with the choice of RA treatment and
the outcome (MSD-related hospitalizations). In addition,
our data included an index of socioeconomic status (SES),
with sub-indices of social and material deprivation, that
was developed by the Institut National de Santé Publique
du Québec on the basis of census enumeration area data
on education level, employment/population ratio, and
average income [14, 15].
Secondary analyses
In secondary analyses, patient selection, variable
assessment and statistical analyses described above
were repeated for patients on DMARDs and patients
on neither drug, in the three periods (1998–2001,
2002–2006 and 2007–2011). The DMARD group in
this analysis consisted of all patients who used a
DMARD, but had never been on an anti-TNF prior
to the DMARD use, as opposed to the previous ana-
lysis where the DMARD group was selected to
match the anti-TNF group.
Statistical analyses
The following analyses were conducted separately in
each of the study periods. Descriptive analyses [mean
and standard deviation (SD) or proportion] were used
as appropriate to report baseline patient characteris-
tics by treatment group. Polytomous logistic regres-
sion models were used to compare patient baseline
characteristics between the three treatment groups.
The crude rates/100 patient-years (py) of MSD-related
hospitalizations were assessed. Kaplan Meier curve
displayed time to the first MSD-related hospitalization
in the three treatment groups. Multivariable Cox
proportional hazard models were used to compare the
hazard ratios of MSD-related hospitalizations be-
tween treatment groups adjusting for patient baseline
characteristics.
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All statistical analyses described above were repeated
in secondary analyses to compare MSD-related hospital-
izations in the DMARD users versus non-users in the
three time-periods. All statistical analyses were per-
formed using SAS version 9.4 for UNIX (SAS Institute
Inc., Cary, NC).
Results
In total, 10,418 RA individuals were in the 2002–
2006 cohort, and 15,936 in the 2007–2011 cohort
(data not shown). Among these, 557 used anti-TNF,
1144 were matched DMARD users and 656 matched
non-users in 2002–2006; while, 690 used anti-TNF,
1651 were matched DMARD users and 532 matched
non-users in 2007–2011 (Table 1). Among non-
users, 81 % used corticosteroid and/or NSAID in the
follow-up during 2002–2006 compared to 74 % dur-
ing 2007–2011 (Appendix 3).
Patient baseline characteristics
Matching by high-dimensional propensity score, age
and sex, removed most differences in baseline pa-
tient characteristics between the treatment groups
except those related directly to the treatment choice
such as prior corticosteroid and NSAID use, prior
visits to rheumatologists and socioeconomic status
(Table 2). In 2002–2006, patients in the anti-TNF
group and those in the DMARD group had higher
SES compared to non-users and were more likely
than non-users to have taken corticosteroids and
Table 1 Baseline characteristics of individuals with rheumatoid arthritis in Quebec in 2002–2006 and 2007–2011
Variables 2002–2006 2007–2011
Anti-TNF (557) DMARDs (1144) Non-users (656) Anti-TNF (690) DMARDs (1651) Non-users (532)
Demographics
Age (mean (±SD)) years 63.0(11.5) 64.2 (10.8) 65.1 (10.6) 65.2 (10.5) 66.2 (9.7) 68.4 (9.3)
Sex (female N (%)) 426 (76.5) 921 (80.5) 562 (85.7) 517 (74.9) 1281 (77.6) 426 (80.1)
Residence (urban N (%)) 428 (76.8) 899 (78.6) 526 (80.2) 531 (77.0) 1316 (79.7) 425 (79.9)
Higher incomea 344 (61.8) 691 (60.4) 379 (57.8) 417 (60.4) 980 (59.4) 339 (63.7)
Socioeconomic status N (%)
Social quintile 0 58 (10.4) 90 (7.9) 48 (7.3) 49 (7.1) 100 (6.1) 25 (4.7)
Social quintile 1 106 (19.0) 211 (18.4) 88 (13.4) 113 (16.4) 285 (17.3) 74 (13.9)
Social quintile 2–3 192 (34.5) 392 (34.3) 238 (36.3) 251 (36.5) 618 (37.4) 218 (41.0)
Social quintile 4–5 201 (36.1) 451 (39.4) 282 (43.0) 276 (40.0) 648 (39.2) 215 (40.4)
Use of health services in prior year N (%)
Visit to rheumatologist 490 (88.0) 946 (82.7) 480 (73.2) 608 (88.1) 1365 (82.7) 338 (63.5)
Comorbidity in prior year N (%)
Hematologic disorders 75 (13.5) 112 (9.8) 69 (10.5) 72 (10.4) 182 (11.0) 69 (13.0)
Heart failure 16 (2.9) 29 (2.5) 9 (1.4) 19 (2.8) 38 (2.3) 23 (4.3)
Cerebrovascular disease 21 (3.8) 23 (2.0) 19 (2.9) 10 (1.4) 39 (2.4) 22 (4.1)
Atrial fibrillation 14 (2.5) 24 (2.1) 13 (2.0) 23 (3.3) 54 (3.3) 18 (3.4)
Ischemic heart disease 79 (14.2) 138 (12.1) 76 (11.6) 65 (9.4) 186 (11.3) 56 (10.5)
Peptic ulcer disease 7 (1.3) 10 (0.9) 5 (0.8) 1 (0.1) 9 (0.5) 3 (0.6)
Cancer 39 (7.0) 102 (8.9) 51 (7.8) 69 (10.0) 172 (10.4) 64 (12.0)
Medication use in prior year N (%)
NSAIDs 430 (77.2) 843 (73.7) 452 (68.9) 435 (63.0) 980 (59.4) 248 (46.6)
Serotonin reuptake inhibitors 57 (10.2) 107 (9.4) 62 (9.5) 71 (10.3) 164 (9.9) 532 (9.6)
Gastroprotective agents 322 (57.8) 664 (58.0) 345 (52.6) 463 (67.1) 970 (58.8) 328 (61.7)
Antidiabetics 63 (11.3) 115 (10.1) 51 (7.8) 81 (11.7) 170 (10.3) 77 (14.5)
Corticosteroid 414 (74.3) 757 (66.2) 400 (61.0) 500 (72.5) 928 (56.2) 306 (57.5)
Anticoagulants 27 (4.8) 49 (4.3) 31 (4.7) 32 (4.6) 106 (6.4) 34 (6.4)
Antihypertensives 294 (52.8) 587 (51.3) 305 (46.5) 414 (60.0) 944 (57.2) 335 (63.0)
aThose who do not receive any guaranteed income supplement
Machado et al. BMC Musculoskeletal Disorders  (2016) 17:298 Page 4 of 10
NSAIDs and to have visited a rheumatologist in the previ-
ous year. In 2007–2011, patients in the anti-TNF group
were more likely than non-users to live in rural areas, to
have received partial or total subsidies, to have used cor-
ticosteroid and NSAIDs and to have seen a rheumatologist
in the previous year. They were also less likely to have
CVD. In 2007–2011, patients in the DMARD group were
more likely than non-users to have received partial or total
subsidies, to have taken NSAIDs and visited a rheuma-
tologist in the previous year. They were also less likely to
have CHF and to have been using antidiabetics.
Hospitalizations for MSD-related events
The total number of patients who had MSD-related
hospitalisations in 2002–2006 and 2007–2011 are dis-
played in Table 3. In 2002–2006, among the anti-TNF
group, 39 individuals were hospitalized (crude rate
8.2/100 py), compared to 63 patients (6.4/100 py)
among the DMARDs group and 53 patients (10.5/100
py) among the non-users group. While, in 2007–2011,
40 patients among the anti-TNF group were hospital-
ized for MSD-related events (6.8/100 py), compared
to 70 patients (4.8/100 py) among the DMARDs
group and 35 patients (8.6/100 py) among the non-
user group. Figure 1 displays the Kaplan Meier curves
of time to first MSD-related hospitalizations in the
three treatment groups. In stratified multivariate Cox
proportional hazard models, ischemic heart disease
increased the risk of MSD-related hospitalizations in
both periods. Use of antihypertensive agents in the
previous year was negatively associated with MSD-
related hospitalization in 2002–2006. Prior visits to
rheumatologists were associated with a decreased risk
of MSD-related hospitalizations in 2007–2011
(Table 4). In these models, the risk of MSD-related
hospitalizations did not differ between anti-TNF users
and non-users (0.95, 0.60, 1.50) in 2002–2006. The
risk in that period tended to be lower in DMARD
users 0.69 (0.46, 1.02). In 2007–2011, the risk in anti-
TNF users tended to be lower than that in non-users,
Table 2 Patient characteristics associated with anti-TNF and DMARD use: logistic regression model
Variables 2002–2006 2007–2011
OR (95 % CI) OR (95 % CI)
Anti-TNF vs Non-users DMARDs vs Non-users Anti-TNF vs Non-users DMARDs vs Non-users
Demographics
Residence (rural vs urbain) 1.21 (0.88, 1.66) 1.05 (0.81, 1.38) 1.43 (1.05, 1.96) 1.15 (0.87, 1.51)
Higher income 1.14 (0.90, 1.46) 1.02 (0.83, 1.26) 0.76 (0.59, 0.98) 0.70 (0.56, 0.87)
Socioeconomic status
Social quintile 0 1.02 (0.62, 1.68) 0.75 (0.48, 1.17) 1.33 (0.73, 2.41) 1.00 (0.59, 1.71)
Social quintile 2–3 versus 1 0.69 (0.48, 0.98) 0.69 (0.51, 0.93) 0.71 (0.49, 1.01) 0.72 (0.53, 0.98)
Social quintile 4–5 versus 1 0.61 (0.43, 0.88) 0.66 (0.49, 0.90) 0.82 (0.57, 1.18) 0.74 (0.54, 1.01)
Use of health services in prior year
Visit to rheumatologist 2.73 (1.97, 3.79) 1.74 (1.36, 2.22) 4.41 (3.27, 5.95) 2.86 (2.29, 3.60)
Comorbidity in prior year
Hematologic disorders 1.32 (0.90, 1.94) 0.92 (0.66, 1.28) 0.88 (0.60, 1.30) 0.96 (0.69, 1.32)
Heart failure 1.97 (0.84, 4.61) 1.95 (0.89, 4.29) 0.82 (0.41, 1.63) 0.52 (0.28, 0.94)
Cerebrovascular disease 1.43 (0.74, 2.75) 0.75 (0.39, 1.42) 0.38 (0.16, 0.86) 0.63 (0.35, 1.14)
Ischemic heart disease 1.06 (0.72, 1.55) 0.90 (0.64, 1.26) 0.97 (0.63, 1.50) 1.33 (0.93, 1.91)
Cancer 0.86 (0.55, 1.35) 1.17 (0.81, 1.69) 0.82 (0.56, 1.20) 0.88 (0.64, 1.22)
Medication use in prior year
NSAIDs 1.59 (1.21, 2.09) 1.26 (1.02, 1.58) 1.87 (1.46, 2.40) 1.66 (1.35, 2.05)
Serotonin reuptake inhibitors 0.93 (0.62, 1.39) 0.90 (0.65, 1.26) 1.08 (0.72, 1.63) 1.12 (0.79, 1.60)
Gastroprotective agents 1.04 (0.81, 1.33) 1.18 (0.95, 1.45) 1.09 (0.84, 1.42) 0.85 (0.68, 1.06)
Antidiabetics 1.39 (0.93, 2.08) 1.28 (0.89, 1.83) 0.76 (0.52, 1.09) 0.71 (0.53, 0.97)
Corticosteroid 1.87 (1.44, 2.43) 1.22 (0.99, 1.50) 1.92 (1.49, 2.47) 0.96 (0.78, 1.18)
Anticoagulants 0.90 (0.50, 1.62) 0.84 (0.52, 1.37) 0.98 (0.56, 1.71) 1.39 (0.89, 2.19)
Antihypertensives 1.21 (0.94, 1.57) 1.20 (0.97, 1.48) 0.93 (0.72, 1.21) 0.85 (0.68, 1.06)
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Fig. 1 Time to admission to the first hospitalization for a musculoskeletal condition: Kaplan Meier curves
Table 3 Exposure duration, unadjusted rates and adjusted rate ratios (Cox proportional hazard models) of musculoskeletal
hospitalizations in 2002–2006 and 2007–2011
Exposure duration (days) Hospitalization for musculoskeletal conditions
Total Median (interquartile range) Number (unadjusted rate per 100 patient-yrs) Hazard ratio (95 % CI)
2002–2006
Anti-TNF 174 128 365.0 (79.0) 39 (8.18) 0.95 (0.60, 1.50)
DMARDs 358 954 365.0 (74.0) 63 (6.41) 0.69 (0.46, 1.02)
Non-user 184 986 349.0 (173.0) 53 (10.46) 1.00 (Reference)
2007–2011
Anti-TNF 213 189 365.0 (102.0) 40 (6.85) 0.65 (0.37, 1.14)
DMARDs 527 820 635.0 (54.0) 70 (4.84) 0.40 (0.24, 0.66)
Non-user 148 381 349.5 (181.0) 35 (8.61) 1.00 (Reference)
CI confidence interval
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although statistical significance was not reached (0.65;
0.37, 1.14). The risk in the DMARDs group was lower
than that in non-users during this period (0.40; 0.24,
0.66).
Secondary analyses
Repeating the selection of cohorts and analyses
among DMARDs users and non-users in 1998–2001,
2002–2006 and 2007–2011 revealed that in total,
3844 individuals used DMARDs and 7356 were
matched non-users in 1998–2001; compared to 5978
DMARDs users and 11,439 matched non-users in
2002–2006; and 8260 DMARDs users and 15,361
matched non-users in 2007–2011. The total numbers
of patients who were hospitalized for MSD-related
events in the three periods are displayed in Table 5
by treatment group. In 1998–2001, the numbers of
hospitalized patients (crude rate/100 py) were 229
(6.7/100 py) in the DMARD and 362 (6.6/100 py) in
the non-user groups. While, in 2002–2006, they were
289 (5.4/100 py) in the DMARD and 614 (6.9/100 py)
in the non-user groups; and in 2007–2011, they were
344 (4.5/100 py) in the DMARD and 797 (7.3/100 py)
in the non-users groups. In multivariable Cox propor-
tional Hazard models, the hazard ratios of MSD-
related hospitalizations in the DMARD versus non-
users groups were 1.16 (0.95, 1.41) in 1998–2001,
0.86 (0.73, 1.01) in 2002–2006 and 0.71 (0.60, 0.84) in
2007–2011.
Discussion
Our results suggests that in RA patients, the risks of
MSD-related hospitalizations were similarly likely for
those using anti-TNF therapy compared to non-
users. The risk seemed higher in the first 5 years
after the introduction of anti-TNF drugs to the mar-
ket compared to the following 7–11 years. In
DMARDs users that matched the anti-TNF users,
MSD-related hospitalizations were less likely than in
non-users in both periods, although results reached
statistical significance in the second period. Analyses
of all DMARD users revealed a similar risk among
DMARD users compared to non-users in the period
preceding the introduction of the anti-TNF to the
market and a decreasing trend showing a lower risk
among DMARD users in the following two periods.
The apparently lower risk found in DMARD versus
anti-TNF users is not surprising as anti-TNFs can
only be prescribed in Quebec when DMARD therapy
has failed. However, the higher risk of MSD-related
hospitalizations among non-users is somehow con-
cerning. The reasons for not using DMARDs or
anti-TNF therapy during the study period among
non-users was not known in our study. Further
examination of the data revealed that the majority of
non-users (81 % in 2002–2006 and 74 % in 2007–
2011) used corticosteroid and/or NSAID in the
follow-up. However, this alone cannot explain the
higher hospitalization rate observed among non-
users since the anti-TNF and DMARD groups also
used these mediations in follow-up in similar to
slightly higher proportions. In another published
study, treatment discontinuation among RA patients
reflected more the individual patient beliefs regard-
ing treatment necessity and safety than the actual
disease activity or route of drug administration [16].
Table 5 Secondary analyses comparing Hospitalizations for
musculoskeletal conditions among DMARDs users and
non-users before and after the introduction of anti-TNF











DMARDs 1,243,393 365.0 (12.0) 229 (6.72) 1.16
(0.95, 1.41)
Non-users 1,998,164 317.0 (193.0) 362 (6.61) 1.00
(Reference)
2002–2006
DMARDs 1,949,824 365.0 (0.0) 289 (5.41) 0.86
(0.73, 1.01)
Non-users 3,270,739 365.0 (169.0) 614 (6.85) 1.00
(Reference)
2007–2011
DMARDs 2,785,950 365.0 (0.0) 344 (4.51) 0.71
(0.60, 0.84)
Non-users 3,970,012 296.0 (224.0) 797 (7.33) 1.00
(Reference)
CI confidence interval
Table 4 Patients characteristics associated with hospitalization
for musculoskeletal conditions: Cox proportional hazard models
adjusted for treatment group at baseline
Demographics 2002–2006 2007–2011
Use of health services in prior year
Visit to Rheumatologist - 0.51 (0.30, 0.86)
Comorbidity in prior year
Ischemic heart disease 2.34 (1.32, 4.13) 2.69 (1.38, 5.22)
Medication use in prior year
Antihypertensives 0.71 (0.47, 1.08) -
Also adjusted for patient characteristics listed in Table 2. Only significant
associations are reported in this table
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In a second study, about half of RA patients pre-
scribed methotrexate interrupted their treatment
within 1 year; these patients had higher disease ac-
tivity compared to those who remained on treatment
[17]. We also cannot rule out the possibility that
anti-TNF use increased complication awareness
which may have prompted physician contacts at the
onset of symptoms and prevented deterioration re-
quiring hospitalizations.
Few studies have considered admission to hospital
as an effectiveness indicator of anti-TNF and
DMARDs use. An Israeli study reported a decreased
frequency of the number of all-cause hospitalizations
during anti-TNF treatment compared to the period
before treatment among patients with RA and spon-
dyloarthropathies (44.2 versus 74.2 hospitalizations/
100 py, p-value < 0.0001). The authors reported simi-
lar tendency related to hospitalizations due to ex-
acerbation of the rheumatic disease (21.9 versus
47.5/100 py, p <0.0001) and for orthopedic and sur-
gical indications, however the latter analyses did not
reach statistical significance [9]. A Japanese study
reported no significant yearly difference in the preva-
lence of RA-related surgery after the introduction of
anti-TNF drugs between 2004 and 2007, however a
significantly higher proportion was observed for spe-
cific orthopedic surgery, starting in the second year.
Among anti-TNF users, patients who had undergone
RA-related surgery presented longer disease duration
and higher functional disability compared to those
who had not undergone this procedure [8]. Both of
these studies were conducted shortly after the ap-
proval of anti-TNF drugs for the treatment of RA in
their respective countries.
In our study, the decreasing trend of MSD-related
hospitalizations found among DMARDs users over
the three periods compared to the non-users per-
haps, reflects the migration of the more severe cases
from the DMARDs group after the approval of anti-
TNF for reimbursement and over time.
Our study assessed the risk of MSD-related hospi-
talizations only. Hospitalizations for other reasons
(including infections) are also important outcomes in
RA patients, but were not within our study aim and
were not investigated. Confounding by indication can
greatly hinder the results of observational studies,
because of the non-randomized nature of patient
allocation to study treatments. The use of the pro-
pensity score methodology has been proposed to
address this bias [18]. In our study, we used the
high-dimensional propensity score to match patients
in the treatment groups and create more balanced
exposed and non-exposed groups [10]. In addition,
we addressed selection bias in the design by
constructing separate cohorts in two post-periods
that separated the years immediately after the launch
of the anti-TNF drugs (2002–2006) where channeling
of more severe RA cases to anti-TNF treatment was
very strong, from later years (2007–2011) where
channeling remained but may have been less severe
than that of earlier years [3, 5, 19–21].
Conclusion
In conclusion, the results of this population-based study
suggest that the risk of MSD-related hospitalizations is
lower in patients using DMARD alone versus those not
using DMARD or anti-TNF therapy. The risk of MSD-
related hospitalizations in those in whom DMARDs only
has failed and are put on anti-TNF (with or without
DMARDs) was similar to that of patients not using
either of these therapies. Similar risks in patients not
using DMARD or anti-TNF treatment to that of those
using anti-TNF, presumably the more severe, indicate
that some RA patients requiring treatment are not using




Frequency of MSD disorders coded as principal diag-
noses among study individuals hospitalized for MSD
conditions.
Table 6 Frequency of MSD disorders coded as principal







Total number of patients




(ICD-9: 714; ICD-10: M05, M06)
67 (43.23) 37 (25.52)
Osteoarthrosis and allied disorders
(ICD-9: 715; ICD-10: M16- M19)
21 (13.55) 51 (35.17)
Acquired deformities of joints
(ICD-9:717, 730, 733, 735, 736;
ICD-10: M20-M24, M80, M84-87)
29 (18.72) 26 (17.93)
Other and unspecified disorders
of back (ICD-9: 720–722, 724;
ICD-10: M47, M48, M54)
19 (12.27) 8 (5.52)
Other disorders of synovium, tendon,
and bursa (ICD-9: 726, 727, 728; ICD-10:
M62, M65, M66, M70, M71, 75)
9 (5.82) 17 (8.35)
Other: ICD-9: 710, 716, 719, 729 ICD-10:
M00, M13, M60, M72,M99
10 (6.46) 6 (4.14)
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Appendix 2
Frequency of the primary diagnoses of MSD hospita-
lizations during the period 2007–2011 (ICD-10 codes, as
recorded in the database, are listed in alphabetical order).
Appendix 3
Use of NSAIDs and/or corticosteroids in follow-up.
Descriptions of data: Frequency of MSD disorders coded
as principal diagnoses among study individuals hospita-
lized for MSD conditions. Frequency of the primary
diagnoses of MSD hospitalizations during the period
2007–2011 (ICD-10 codes, as recorded in the database,
are listed in alphabetical order). Use of NSAIDs and/or
corticosteroids in follow-up
Abbreviations
CHF, congestive heart failure ; CVD, cerebrovascular disease; DMARDs,
disease modifying antirheumatic drugs ; ICD, Régie de l’assurance maladie
du Québec ; MSD, musculoskeletal ; NSAIDs, Régie de l’assurance maladie
du Québec ; Py, patient-years; RA, Rheumatoid arthritis ; RAMQ, Régie de
l’assurance maladie du Québec; RCT, musculoskeletal ; SD, standard deviation ;
SES, socioeconomic status ; SSRI, serotonin reuptake inhibitors ; TNF, Tumor
Necrosis Factor
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Table 7 Frequency of the primary diagnoses of MSD
hospitalizations during the period 2007–2011 (ICD-10 codes,
as recorded in the database, are listed in alphabetical order)
N (%)
Total number of patients hospitalized for MSD
conditions during 2007–2011
145
M0097; pyogenic arthritis, unspecified, ankle and foot 1 (0.7)
M051, M053, M059 (rheumatoid lung disease n = 1;
rheumatoid arthritis with involvement of other organs
n = 3; seropositive rheumatoid arthritis, unspecified site n = 2)
6 (4.2)
M063, M068, M069 (rheumatoid nodule; n = 6; other
specified rheumatoid arthritis, n = 1; rheumatoid arthritis,
unspecified; n = 24)
31
(21.4)
M1315, M1397 (monoarthritis, pelvic region and thigh,
n = 1; arthritis, unspecified, ankle and foot, n = 1)
2 (1.4
M167, M169 (coxarthrosis, secondary, n = 2; unspecified, n = 9) 11 (7.6)
M171, M179 (gonarthrosis, primary n = 5; unspecified, n = 28) 33
(22.8)
M189; arthrosis of first carpometacarpal joint, unspecified 2 (1.4)
M190, M199 (arthrosis, primary of other joints,
n = 2; unspecified, n = 3)
5 (3.5)
M201, M202, M204 (hallux valgus, n = 9; hallux rigidus,
n = 2; other hammer toe(s) (acquired), n = 1)
12 (8.3)
M2183; other specified acquired deformities of limbs, forearm 1 (0.7)
M224; chondromalacia patellae 1 (0.7)
M2320; derangement of meniscus due to old tear or injury,
multiple sites
1 (0.7)
M2411; other articular cartilage disorders, shoulder region 1 (0.7)
M2587; other specified joint disorders, ankle and foot 1 (0.7)
M313; Wegener's granulomatosis 2 (1.4)
M4802, M4806, M4856 (Spinal stenosis, cervical region,
n = 1; lumbar region, n = 3; collapsed vertebra,
lumbar region, n = 1)
5 (3.5)
M545; low back pain 3 (2.1)
M6096; myositis, unspecified, lower leg 1 (0.7)
M6227, M6289 (ischaemic infarction of muscle, ankle and
foot, n = 1; other specified disorders of muscle,
unspecified site, n = 1)
2 (1.4)
M6593, M6289, M6596 (synovitis and tenosynovitis, forearm, n
= 1; hand, n = 1; lower leg, n = 1)
3 (2.1)
M6657; spontaneous rupture of unspecified tendon, ankle and
foot
1 (0.7)
M702; olecranon bursitis 2 (1.4)
M703; other bursitis of elbow 1 (0.7)
M7134, M7136, M7192 (other bursal cyst, hand, n = 2;
lower leg, n = 1; bursopathy, unspecified,
upper arm, n = 1)
4 (2.8)
Table 7 Frequency of the primary diagnoses of MSD
hospitalizations during the period 2007–2011 (ICD-10 codes,
as recorded in the database, are listed in alphabetical order)
(Continued)
M7263, M7192 (necrotizing fasciitis, forearm,
n = 1, pelvic region and thigh, n = 1)
2 (1.4)
M751, M758 (rotator cuff syndrome, n = 1; other shoulder
lesions, n = 1)
2 (1.4)
M8098; unspecified osteoporosis with pathological fracture,
other site
1 (0.7)
M8448; pathological fracture, not elsewhere classified, other
site
2 (1.4)
M8558; aneurysmal bone cyst, other site 1 (0.7)
M8617, M8697 (osteomyelitis ankle and foot, acute n = 1,
unspecified n = 3)
4 (2.8)
M8795; osteonecrosis, unspecified, pelvic region and thigh 1 (0.7)
Table 8 Use of NSAIDs and/or corticosteroids in follow-up
Anti-TNF DMARDs Non- users
2002–2006
Total number of patients 557 1144 656
NSAIDs in follow-up 372 (66.8) 788 (68.9) 451 (68.8)
Corticosteroid in follow-up 344 (61.8) 650 (56.8) 353 (53.8)
NSAIDs and/or corticosteroid
in follow-up
460 (82.6) 959 (84.7) 531 (80.9)
2007–2012
Total number of patients 690 1651 532
NSAIDs in follow-up 389 (56.4) 981 (59.4) 257 (48.3)
Corticosteroid in follow-up 413 (59.9) 790 (47.8) 276 (51.9)
NSAIDs and/or corticosteroid
in follow-up
568 (82.3) 1251 (75.8) 396 (74.4)
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